Pegcetacoplan ophthalmic · Syfovre
Peptide
Evidence outlook
Approved: Age-Related Macular Degeneration
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (1)
- Geographic atrophy secondary to age-related macular degeneration (every other month, adults with intact fovea)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03525613 NCT03525613 · Geographic Atrophy This was a randomized, quadruple-blind, sham-controlled trial with 637 participants. Its primary clinical imaging endpoint—change in geographic-atrophy lesion area at month 12—was statistically met for both monthly pegcetacoplan versus pooled sham (difference −0.4114 mm²; p=0.0004) and every-other-month pegcetacoplan versus pooled sham (difference −0.3180 mm²; p=0.0055). Registry: NCT03525613 | 3 | Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12) 2021-06-28 | Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.5579 mm^2 (Standard Error 0.0835) | Pegcetacoplan EOM 1.6512 mm^2 (Standard Error 0.08118) vs Sham Pooled 1.9692 mm^2 (Standard Error 0.08218) | Reliable signal | link ↗ |
View 1 more trial
NCT03525600 NCT03525600 · Geographic Atrophy The study was randomized, quadruple-masked, and sham-controlled, with 621 participants. Its clinical primary endpoint—change in geographic atrophy lesion area at Month 12—was not statistically significant for either monthly treatment (p=0.0615) or every-other-month treatment (p=0.0854), so the results provide well-controlled but inconclusive evidence of benefit. Registry: NCT03525600 | 3 | Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12) 2021-06-21 | Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.7344 mm^2 (Standard Error 0.07924) | Pegcetacoplan EOM 1.7563 mm^2 (Standard Error 0.07446) vs Sham Pooled 1.964 mm^2 (Standard Error 0.09592) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 1/2 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
Other Complement C3 drugs
Pegcetacoplan, Cevolisiran, ARO-C3. Compare all 4 Complement C3 drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Age-Related Macular Degeneration: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Pegcetacoplan Ophthalmic (Syfovre): this drug | Approved | Peptide | Complement C3, Complement C3 / C3b | Reliable signal | NCT03525613: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.5579 mm^2 (Standard Error 0.0835) | Pegcetacoplan EOM 1.6512 mm^2 (Standard Error 0.08118) vs Sham Pooled 1.9692 mm^2 (Standard Error 0.08218) NCT03525600: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.7344 mm^2 (Standard Error 0.07924) | Pegcetacoplan EOM 1.7563 mm^2 (Standard Error 0.07446) vs Sham Pooled 1.964 mm^2 (Standard Error 0.09592) missed | |
| Aflibercept (Eylea) | Approved | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | Reliable signal | NCT00509795: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) NCT00637377: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (At week 52): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 95.62% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 96.27% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 95.56% vs Ranibizumab 0.5mg Q4 94.42% | |
| Aflibercept-Abzv (Enzeevu) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Ayyh (Pavblu) | Approved | Protein / enzyme therapeutic | VEGF-A | Reliable signal | NCT04270747: Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) | |
| Aflibercept-Boav (Eydenzelt) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Jbvf (Yesafili) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Mrbb (Ahzantive) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Yszy (Opuviz) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Avacincaptad Pegol (Izervay) | Approved | RNA Aptamer | Complement C5 | Reliable signal | NCT04435366: 12-month geographic-atrophy growth: 0.336 vs 0.392 mm/year for avacincaptad pegol vs sham; difference 0.056 mm/year (95% CI 0.016 to 0.096; p=0.0064). 24-month geographic-atrophy growth: 2.23 vs 2.59 mm²/year for monthly avacincaptad pegol vs sham; difference 0.362 mm²/year (95% CI 0.066 to 0.657; p=0.0165). NCT02686658: Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence (Baseline and 12 months): Zimura 2 mg [Part 1 & Part 2 Combined] 0.292 millimeters (mm) (Standard Error 0.077) | Zimura 4 mg [Part 2] 0.321 millimeters (mm) (Standard Error 0.074) vs Sham [Part 1 & Part 2 Combined] 0.402 millimeters (mm) (Standard Error 0.075) | Sham [Part 2] 0.444 millimeters (mm) (Standard Error 0.072) | |
| Brolucizumab-Dbll | Approved | Antibody fragment | VEGF-A | Weak signal | No reviewed efficacy summary in this indication | |
| Faricimab | Approved | Multispecific antibody | Angiopoietin-2 / VEGF-A | Partial signal | NCT03823287: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 5.8 vs 5.1 letters, adjusted mean difference 0.7 (95% CI -1.1 to 2.5); lower bound above the -4 letter non-inferiority margin (CT.gov posted results). NCT03823300: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 6.6 vs 6.6 letters, adjusted mean difference 0.0 (95% CI -1.7 to 1.8); lower bound above the -4 letter non-inferiority margin (CT.gov posted results). | |
| Pegcetacoplan (Empaveli) | Approved(overall) | Peptide | Complement C3 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab (Lucentis) | Approved | Antibody fragment | VEGF-A | Partial signal | NCT00056836: Losing fewer than 15 letters at 12 months: 94.5% (0.3 mg) and 94.6% (0.5 mg) vs 62.2% sham. | |
| Ranibizumab-Eqrn (Cimerli) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab-Hkdz (Ranluspec) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab-Leyk (Nufymco) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab-Nuna (Byooviz) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Verteporfin (Visudyne) | Approved | Small molecule | Benzoporphyrin-derivative photosensitizer for photodynamic therapy | Partial signal | NCT00436553: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 (Baseline and Month 12): Verteporfin SF + Ranibizumab — Baseline: 53.7 Letters (Standard Deviation 13.52); Month 12: 59 Letters (Standard Deviation 17.47); Change from baseline: 5.3 Letters (Standard Deviation 15.66) | Verteporfin RF + Ranibizumab — Baseline: 54.6 Letters (Standard Deviation 12.78); Month 12: 59 Letters (Standard Deviation 18.03); Change from baseline: 4.4 Letters (Standard Deviation 15.47) vs Ranibizumab Monotherapy — Baseline: 54.8 Letters (Standard Deviation 13.55); Month 12: 63 Letters (Standard Deviation 18.88); Change from baseline: 8.1 Letters (Standard Deviation 15.09) missed NCT00121407: VIO trial, 24-month primary endpoint: 47% of verteporfin-PDT patients vs 53% of placebo patients lost ≥15 letters (not significant); source states n=384 vs task record's 364, but sponsor/design/QLT-era details match this trial (2:1 randomization, occult CNV, no classic component). missed | |
| Axitinib Intravitreal Implant (OTX-TKI) | Phase 3 | Small molecule | VEGF receptors + PDGF receptors | Partial signal | NCT06223958: Superiority primary endpoint at week 36: 74.1% with AXPAXLI vs 55.8% with aflibercept 2 mg lost fewer than 15 ETDRS letters (2026-02-17). | |
| BAT5906 | Phase 3 | Monoclonal antibody | VEGF-A | Partial signal | No reviewed efficacy summary in this indication | |
| Cemdisiran | Phase 3 | RNA / oligonucleotide | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| CKD-701 (Lucenbies) | Phase 3 | Monoclonal antibody | VEGF-A | Reliable signal | NCT04857177: Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%). | |
| HLX04-O | Phase 3 | Monoclonal antibody | VEGF-A | Partial signal | No reviewed efficacy summary in this indication | |
| Pozelimab (Veopoz) | Phase 3 | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Ximluci) | Phase 3 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| RC28-E | Phase 3 | Protein / enzyme therapeutic | VEGF-A / FGF-2 (dual blockade) | Partial signal | NCT04270669: Mean BCVA improvement from baseline at week 48: 6.1 ± 8.3 letters (0.5 mg), 9.9 ± 10.7 letters (1.0 mg), 7.6 ± 9.4 letters (2.0 mg) | |
| Surabgene Lomparvovec | Phase 3 | Gene therapy / editing | VEGF-A | Weak signal | NCT04832724: Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0 | |
| Tabirafusp Tedromer | Phase 3 | Multispecific antibody | VEGF + IL-6 | Partial signal | NCT06556368: Primary endpoint: tabirafusp tedromer non-inferior to aflibercept on vision (p=0.0036); anatomical key secondary endpoint p<0.0001 (DAYBREAK, 2026-09-28). | |
| Tarcocimab Tedromer | Phase 3 | Monoclonal antibody | VEGF-A | Partial signal | NCT04964089: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76) NCT06556368: Primary endpoint, BCVA: met (p=0.0007) (Kodiak topline, 2026-09-28). | |
| Vonaprument | Phase 3 | Antibody fragment | Complement C1q | Partial signal | NCT04656561: GA lesion growth vs sham at 12 months: 6.2% reduction monthly (p=0.526), 1.3% every-other-month (p=0.896), 3.7% pooled (p=0.673); primary endpoint not statistically significant. missed | |
| MW02 | Phase 2/3 | Monoclonal antibody | VEGF-A | Partial signal | No reviewed efficacy summary in this indication | |
| BI 1584862 | Phase 2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| BI 771716 | Phase 2 | Antibody fragment | — | Weak signal | Featured results are safety only in this race | |
| Cevolisiran | Phase 2(overall) | RNA / oligonucleotide | Complement C3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Iptacopan (Fabhalta) | Phase 2 | Small molecule | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-6628 | Phase 1/2 | Antibody fragment | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| ARO-C3 | Phase 1/2(overall) | RNA / oligonucleotide | Complement C3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| SAR402663 | Phase 1/2 | Gene therapy / editing | VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| SAR446597 | Phase 1/2 | Gene therapy / editing | Complement C1s + Factor Bb | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Rimmyrah) | Phase 1 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Afiveg) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Eyluxvi) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Mynzepli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Vgenfli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Ranivisio) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Rexatilux) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Lazucirnon | Discontinued | Small molecule | CCR3 | Partial signal | NCT04331730: Mean change in BCVA (ETDRS letters) from baseline to Week 36: AKST4290 800 mg + aflibercept +10.4 (SD 10.26, n=36), AKST4290 1600 mg + aflibercept +6.7 (SD 7.89, n=35), placebo + aflibercept +13.7 (SD 7.60, n=36); no between-group analysis posted (CT.gov posted results). |
Upcoming events
No upcoming readouts on record for this asset.